Skip to main content
Erschienen in: International Journal of Clinical Oncology 4/2023

16.02.2023 | Original Article

Macroscopic and multiple metastases in sentinel lymph node biopsy are respectively associated with poor prognosis in early oral cancer

verfasst von: Takahito Kondo, Kiyoaki Tsukahara, Daisuke Kawakita, Seiichi Yoshimoto, Kouki Miura, Masashi Sugasawa, Kazuaki Chikamatsu, Takashi Matsuzuka, Isao Oze, Morimasa Kitamura, Yoshiko Murakami, Shinji Otozai, Takeshi Shinozaki, Shinichi Ohba, Koji Araki, Takatsugu Mizumachi, Dai Sato, Naohiro Wakisaka, Hitoshi Hirakawa, Yasuhisa Hasegawa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

A multicenter, randomized controlled phase III trial was conducted on sentinel lymph node biopsy (SLNB) and elective neck dissection for T1 (depth of invasion ≥ 4 mm)–T2N0M0 oral cavity squamous cell carcinoma. This study identified factors associated with poor prognosis in patients who underwent SLNB based on a subgroup analysis of this trial.

Methods

We analyzed 418 sentinel lymph nodes (SLNs) from 132 patients who underwent SLNB. The metastatic SLNs were classified into three categories based on size-isolated tumor cells: < 0.2 mm, micrometastasis: ≥ 0.2 mm and < 2 mm, and macrometastasis: ≥ 2 mm. Three groups were formed based on the number of metastatic SLNs: no metastasis, 1 metastatic node, and ≥ 2 metastatic nodes. The size and number of metastatic SLNs on survival were evaluated using Cox proportional hazard models.

Results

Patients with macrometastasis and ≥ 2 metastatic SLNs had worse overall survival (OS) and disease-free survival (DFS) after adjustment for potential confounders (HR for OS: macrometastasis, 4.85; 95% CI 1.34–17.60; ≥ 2 metastatic SLN, 3.63; 95% CI 1.02–12.89; HR for DFS: macrometastasis, 2.94; 95% CI 1.16–7.44; ≥ 2 metastatic SLN, 2.97; 95% CI 1.18–7.51).

Conclusions

In patients who underwent SLNB, a poorer prognosis was associated with macrometastasis or having ≥ 2 metastatic SLNs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat D’Cruz AK, Vaish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529CrossRefPubMed D’Cruz AK, Vaish R, Kapre N et al (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373:521–529CrossRefPubMed
2.
Zurück zum Zitat Hasegawa Y, Tsukahara K, Yoshimoto S et al (2021) Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: a randomized, multicenter, and noninferiority trial. J Clin Oncol 39:2025–2036CrossRefPubMed Hasegawa Y, Tsukahara K, Yoshimoto S et al (2021) Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: a randomized, multicenter, and noninferiority trial. J Clin Oncol 39:2025–2036CrossRefPubMed
3.
Zurück zum Zitat Kaul P, Majumdar K, Kumar R et al (2021) Isolated tumor cells in sentinel lymph nodes: a management dilemma. J Clin Oncol 39:3517–3518CrossRefPubMed Kaul P, Majumdar K, Kumar R et al (2021) Isolated tumor cells in sentinel lymph nodes: a management dilemma. J Clin Oncol 39:3517–3518CrossRefPubMed
4.
Zurück zum Zitat Hasegawa Y, Tsukahara K, Yoshimoto S et al (2021) Reply to P. Kaul et al. J Clin Oncol 39:3518–3519CrossRefPubMed Hasegawa Y, Tsukahara K, Yoshimoto S et al (2021) Reply to P. Kaul et al. J Clin Oncol 39:3518–3519CrossRefPubMed
5.
Zurück zum Zitat Miura K, Hirakawa H, Uemura H et al (2017) Sentinel node biopsy for oral cancer: a prospective multicenter phase II trial. Auris Nasus Larynx 44:319–326CrossRefPubMed Miura K, Hirakawa H, Uemura H et al (2017) Sentinel node biopsy for oral cancer: a prospective multicenter phase II trial. Auris Nasus Larynx 44:319–326CrossRefPubMed
6.
Zurück zum Zitat Hermanek P, Hutter RV, Sobin LH et al (1999) International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86:2668–2673CrossRefPubMed Hermanek P, Hutter RV, Sobin LH et al (1999) International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 86:2668–2673CrossRefPubMed
7.
Zurück zum Zitat Alex JC, Krag DN (1996) The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surg Oncol Clin N Am 5:33–41CrossRefPubMed Alex JC, Krag DN (1996) The gamma-probe-guided resection of radiolabeled primary lymph nodes. Surg Oncol Clin N Am 5:33–41CrossRefPubMed
8.
Zurück zum Zitat de Bree R, de Keizer B, Civantos FJ et al (2021) What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020? Eur Arch Otorhinolaryngol 278:3181–3191CrossRefPubMed de Bree R, de Keizer B, Civantos FJ et al (2021) What is the role of sentinel lymph node biopsy in the management of oral cancer in 2020? Eur Arch Otorhinolaryngol 278:3181–3191CrossRefPubMed
9.
Zurück zum Zitat de Boer M, van Deurzen CH, van Dijck JA et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663CrossRefPubMed de Boer M, van Deurzen CH, van Dijck JA et al (2009) Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653–663CrossRefPubMed
10.
Zurück zum Zitat Leidenius MH, Vironen JH, Heikkilä PS et al (2010) Influence of isolated tumor cells in sentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg Oncol 17:254–262CrossRefPubMed Leidenius MH, Vironen JH, Heikkilä PS et al (2010) Influence of isolated tumor cells in sentinel nodes on outcome in small, node-negative (pT1N0M0) breast cancer. Ann Surg Oncol 17:254–262CrossRefPubMed
11.
Zurück zum Zitat Broglie MA, Haerle SK, Huber GF et al (2013) Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival. Head Neck 35:660–666CrossRefPubMed Broglie MA, Haerle SK, Huber GF et al (2013) Occult metastases detected by sentinel node biopsy in patients with early oral and oropharyngeal squamous cell carcinomas: impact on survival. Head Neck 35:660–666CrossRefPubMed
12.
Zurück zum Zitat Schilling C, Stoeckli SJ, Haerle SK et al (2015) Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer 51:2777–2784CrossRefPubMed Schilling C, Stoeckli SJ, Haerle SK et al (2015) Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer. Eur J Cancer 51:2777–2784CrossRefPubMed
13.
Zurück zum Zitat Pedersen NJ, Jensen DH, Hedbäck N et al (2016) Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: a retrospective single-center study. Head Neck 38(Suppl 1):E1033-1040CrossRefPubMed Pedersen NJ, Jensen DH, Hedbäck N et al (2016) Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: a retrospective single-center study. Head Neck 38(Suppl 1):E1033-1040CrossRefPubMed
14.
Zurück zum Zitat Garrel R, Poissonnet G, Moyà PA et al (2020) Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1–T2N0 oral and oropharyngeal cancer. J Clin Oncol 38:4010–4018CrossRefPubMed Garrel R, Poissonnet G, Moyà PA et al (2020) Equivalence randomized trial to compare treatment on the basis of sentinel node biopsy versus neck node dissection in operable T1–T2N0 oral and oropharyngeal cancer. J Clin Oncol 38:4010–4018CrossRefPubMed
15.
Zurück zum Zitat Chone CT, Aniteli MB, Magalhães RS et al (2013) Impact of immunohistochemistry in sentinel lymph node biopsy in head and neck cancer. Eur Arch Otorhinolaryngol 270:313–317CrossRefPubMed Chone CT, Aniteli MB, Magalhães RS et al (2013) Impact of immunohistochemistry in sentinel lymph node biopsy in head and neck cancer. Eur Arch Otorhinolaryngol 270:313–317CrossRefPubMed
16.
Zurück zum Zitat Den Toom IJ, Bloemena E, van Weert S et al (2017) Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. Eur Arch Otorhinolaryngol 274:961–968CrossRef Den Toom IJ, Bloemena E, van Weert S et al (2017) Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. Eur Arch Otorhinolaryngol 274:961–968CrossRef
Metadaten
Titel
Macroscopic and multiple metastases in sentinel lymph node biopsy are respectively associated with poor prognosis in early oral cancer
verfasst von
Takahito Kondo
Kiyoaki Tsukahara
Daisuke Kawakita
Seiichi Yoshimoto
Kouki Miura
Masashi Sugasawa
Kazuaki Chikamatsu
Takashi Matsuzuka
Isao Oze
Morimasa Kitamura
Yoshiko Murakami
Shinji Otozai
Takeshi Shinozaki
Shinichi Ohba
Koji Araki
Takatsugu Mizumachi
Dai Sato
Naohiro Wakisaka
Hitoshi Hirakawa
Yasuhisa Hasegawa
Publikationsdatum
16.02.2023
Verlag
Springer Nature Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 4/2023
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-023-02305-1

Weitere Artikel der Ausgabe 4/2023

International Journal of Clinical Oncology 4/2023 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.